Type |
Details |
Score |
Genotype |
Symbol: |
Braf/Braf Raf1/Raf1 Tg(Nes-cre)1Kln/? |
Background: |
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Raf1/Raf1<+> Tg(Nes-cre)1Kln/? |
Background: |
involves: 129P2/OlaHsd * C57BL/6 * SJL |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf<+> Kras/Kras<+> Tg(Tyr-cre/ERT2)1Lru/? |
Background: |
involves: 129S4/SvJae * C57BL/6 * DBA/2 |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Tyr-cre/ERT2)13Bos/? TgTn(sb-T2/Onc)#Dla/? |
Background: |
involves: 129S6/SvEvTac * FVB/N |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf<+> Kras/Kras<+> |
Background: |
involves: 129S4/SvJae * C57BL/6 |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Kras/Kras<+> Polr2a/Polr2a |
Background: |
involves: 129S1/Sv * 129X1/SvJ |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Polr2a/Polr2a Raf1/Raf1 |
Background: |
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf<+> Cdkn2a/Cdkn2a Tg(Vil1-cre)997Gum/? |
Background: |
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Raf1/Raf1 H2az2/H2az2<+> |
Background: |
involves: 129P2/OlaHsd * C57BL/6J * CBA/J |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Kaul A |
Year: |
2013 |
Journal: |
Genesis |
Title: |
Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. |
Volume: |
51 |
Issue: |
10 |
Pages: |
708-16 |
|
•
•
•
•
•
|
Protein Domain |
Type: |
Domain |
Description: |
RNF149, also known as DNA polymerase-transactivated protein 2, is an E3 ubiquitin-protein ligase that interacts with wild-type v-Raf murine sarcoma viral oncogene homologue B1 (BRAF), a RING domain-containing E3 ubiquitin ligase involved in control of gene transcription, translation, cytoskeletal organization, cell adhesion, and epithelial development. RNF149 induces the ubiquitination of wild-type BRAF and promotes its proteasome-dependent degradation. Mutated RNF149 has been found in some human breast, ovarian, and colorectal cancers. RNF149 contains an N-terminal signal peptide, a protease-associated (PA) domain, a transmembrane (TM) domain and a C-terminal C3H2C3-type RING-H2 finger domain followed by a putative PEST sequence []. |
|
•
•
•
•
•
|
Publication |
First Author: |
Cox AD |
Year: |
2012 |
Journal: |
Cancer Cell |
Title: |
The RAF inhibitor paradox revisited. |
Volume: |
21 |
Issue: |
2 |
Pages: |
147-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Rustgi AK |
Year: |
2013 |
Journal: |
Cancer Cell |
Title: |
BRAF: a driver of the serrated pathway in colon cancer. |
Volume: |
24 |
Issue: |
1 |
Pages: |
1-2 |
|
•
•
•
•
•
|
Publication |
First Author: |
Souroullas GP |
Year: |
2015 |
Journal: |
Cancer Cell |
Title: |
mTOR signaling in melanoma: oncogene-induced pseudo-senescence? |
Volume: |
27 |
Issue: |
1 |
Pages: |
3-5 |
|
•
•
•
•
•
|
Strain |
Attribute String: |
coisogenic, mutant strain, transgenic, insertion |
|
•
•
•
•
•
|
Allele |
Name: |
transgene insertion 2, James A Fagin |
Allele Type: |
Transgenic |
Attribute String: |
Inserted expressed sequence |
|
•
•
•
•
•
|
Strain |
Attribute String: |
mutant strain, coisogenic, insertion |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Tg(TG-BRAF*V600E)2Jaf/? |
Background: |
FVB/N-Tg(TG-BRAF*V600E)2Jaf |
Zygosity: |
ot |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Tg(TG-BRAF*V600E)3Jaf/? |
Background: |
FVB/N-Tg(TG-BRAF*V600E)3Jaf |
Zygosity: |
ot |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Tg(tetO-BRAF*V600E)26Jaf/? Tg(TG-rtTA)30Jaf/? |
Background: |
involves: FVB/N |
Zygosity: |
cx |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> |
Background: |
involves: 129S6/SvEvTac * C57BL/6 |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Virós A |
Year: |
2016 |
Journal: |
Cancer Discov |
Title: |
So You Can Teach Old Fibroblasts New Tricks. |
Volume: |
6 |
Issue: |
6 |
Pages: |
581-3 |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Raf1/Raf1 Tg(Nes-cre)1Kln/? |
Background: |
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Braf/Braf Kras/Kras<+> Polr2a/Polr2a Raf1/Raf1 |
Background: |
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Allele |
Name: |
gene trap ROSA 26, Philippe Soriano; targeted mutation 2, Ralf Kuhn |
Allele Type: |
Targeted |
Attribute String: |
Knockdown, RMCE-ready |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(GFAP-cre)#Gtm/? |
Background: |
involves: 129S6/SvEvTac * C57BL/6 * CBA |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Kaul A |
Year: |
2012 |
Journal: |
Genes Dev |
Title: |
Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. |
Volume: |
26 |
Issue: |
23 |
Pages: |
2561-6 |
|
•
•
•
•
•
|
Publication |
First Author: |
Strohecker AM |
Year: |
2014 |
Journal: |
Cancer Discov |
Title: |
Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. |
Volume: |
4 |
Issue: |
7 |
Pages: |
766-72 |
|
•
•
•
•
•
|
Allele |
Name: |
hypoxanthine phosphoribosyltransferase 1; targeted mutation 1, Pentao Liu |
Allele Type: |
Targeted |
Attribute String: |
RMCE-ready, Transposon concatemer |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
873
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
959
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
637
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
947
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
951
|
Fragment?: |
false |
|
•
•
•
•
•
|
Publication |
First Author: |
Carreira S |
Year: |
2005 |
Journal: |
Nature |
Title: |
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. |
Volume: |
433 |
Issue: |
7027 |
Pages: |
764-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Oldrini B |
Year: |
2018 |
Journal: |
Nat Commun |
Title: |
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. |
Volume: |
9 |
Issue: |
1 |
Pages: |
1466 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kwong LN |
Year: |
2017 |
Journal: |
Cell Rep |
Title: |
Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. |
Volume: |
19 |
Issue: |
7 |
Pages: |
1304-1312 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gembarska A |
Year: |
2012 |
Journal: |
Nat Med |
Title: |
MDM4 is a key therapeutic target in cutaneous melanoma. |
Volume: |
18 |
Issue: |
8 |
Pages: |
1239-47 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ischenko I |
Year: |
2021 |
Journal: |
Nat Commun |
Title: |
KRAS drives immune evasion in a genetic model of pancreatic cancer. |
Volume: |
12 |
Issue: |
1 |
Pages: |
1482 |
|
•
•
•
•
•
|
Publication |
First Author: |
Goodall J |
Year: |
2004 |
Journal: |
Mol Cell Biol |
Title: |
Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. |
Volume: |
24 |
Issue: |
7 |
Pages: |
2915-22 |
|
•
•
•
•
•
|
Publication |
First Author: |
Huang S |
Year: |
2012 |
Journal: |
Cell |
Title: |
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. |
Volume: |
151 |
Issue: |
5 |
Pages: |
937-50 |
|
•
•
•
•
•
|
Publication |
First Author: |
Abu-Safieh L |
Year: |
2011 |
Journal: |
Am J Hum Genet |
Title: |
Mutation of IGFBP7 causes upregulation of BRAF/MEK/ERK pathway and familial retinal arterial macroaneurysms. |
Volume: |
89 |
Issue: |
2 |
Pages: |
313-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fedorenko IV |
Year: |
2013 |
Journal: |
Oncogene |
Title: |
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. |
Volume: |
32 |
Issue: |
25 |
Pages: |
3009-18 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yang Y |
Year: |
2018 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Central role of autophagic UVRAG in melanogenesis and the suntan response. |
Volume: |
115 |
Issue: |
33 |
Pages: |
E7728-E7737 |
|
•
•
•
•
•
|
Publication |
First Author: |
Colomer C |
Year: |
2019 |
Journal: |
Mol Cell |
Title: |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer. |
Volume: |
75 |
Issue: |
4 |
Pages: |
669-682.e5 |
|
•
•
•
•
•
|
Publication |
First Author: |
Rosenbaum SR |
Year: |
2020 |
Journal: |
Cell Rep |
Title: |
FOXD3 Regulates VISTA Expression in Melanoma. |
Volume: |
30 |
Issue: |
2 |
Pages: |
510-524.e6 |
|
•
•
•
•
•
|
Publication |
First Author: |
Huang P |
Year: |
2024 |
Journal: |
Cell Host Microbe |
Title: |
Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. |
Volume: |
32 |
Issue: |
8 |
Pages: |
1365-1379.e10 |
|
•
•
•
•
•
|
Publication |
First Author: |
Moon H |
Year: |
2019 |
Journal: |
Exp Dermatol |
Title: |
Sirt5 is dispensable for BrafV600E -mediated cutaneous melanoma development and growth in vivo. |
Volume: |
28 |
Issue: |
1 |
Pages: |
83-85 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhang P |
Year: |
2022 |
Journal: |
Nat Commun |
Title: |
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. |
Volume: |
13 |
Issue: |
1 |
Pages: |
1588 |
|
•
•
•
•
•
|
Publication |
First Author: |
Muta Y |
Year: |
2023 |
Journal: |
Nat Commun |
Title: |
Enhanced SREBP2-driven cholesterol biosynthesis by PKCλ/ι deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis. |
Volume: |
14 |
Issue: |
1 |
Pages: |
8075 |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
80
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
205
|
Fragment?: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Peyret V |
Year: |
2018 |
Journal: |
Mol Cancer Res |
Title: |
Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK-Induced ETS1 Transcriptional Activity. |
Volume: |
16 |
Issue: |
5 |
Pages: |
833-845 |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Fabp7-cre,-lacZ)3Gtm/? |
Background: |
involves: 129S6/SvEvTac * C57BL/6 * CBA |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Yang G |
Year: |
2007 |
Journal: |
Cancer Res |
Title: |
Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. |
Volume: |
67 |
Issue: |
12 |
Pages: |
5649-57 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lyustikman Y |
Year: |
2008 |
Journal: |
Neoplasia |
Title: |
Constitutive activation of Raf-1 induces glioma formation in mice. |
Volume: |
10 |
Issue: |
5 |
Pages: |
501-10 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kwong LN |
Year: |
2012 |
Journal: |
Nat Med |
Title: |
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. |
Volume: |
18 |
Issue: |
10 |
Pages: |
1503-10 |
|
•
•
•
•
•
|
Publication |
First Author: |
Shah M |
Year: |
2010 |
Journal: |
PLoS Genet |
Title: |
A role for ATF2 in regulating MITF and melanoma development. |
Volume: |
6 |
Issue: |
12 |
Pages: |
e1001258 |
|
•
•
•
•
•
|
Publication |
First Author: |
van Schanke A |
Year: |
2006 |
Journal: |
Cancer Res |
Title: |
Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. |
Volume: |
66 |
Issue: |
5 |
Pages: |
2608-15 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yang H |
Year: |
2017 |
Journal: |
Oncogene |
Title: |
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. |
Volume: |
36 |
Issue: |
27 |
Pages: |
3842-3851 |
|
•
•
•
•
•
|
Publication |
First Author: |
Young HL |
Year: |
2017 |
Journal: |
J Exp Med |
Title: |
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. |
Volume: |
214 |
Issue: |
6 |
Pages: |
1691-1710 |
|
•
•
•
•
•
|
Publication |
First Author: |
DeNicola GM |
Year: |
2011 |
Journal: |
Nature |
Title: |
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. |
Volume: |
475 |
Issue: |
7354 |
Pages: |
106-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tzenaki N |
Year: |
2024 |
Journal: |
Commun Biol |
Title: |
A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer. |
Volume: |
7 |
Issue: |
1 |
Pages: |
26 |
|
•
•
•
•
•
|
Publication |
First Author: |
Doma E |
Year: |
2013 |
Journal: |
Cancer Res |
Title: |
Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK. |
Volume: |
73 |
Issue: |
23 |
Pages: |
6926-37 |
|
•
•
•
•
•
|
Publication |
First Author: |
Jameson KL |
Year: |
2013 |
Journal: |
Nat Med |
Title: |
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. |
Volume: |
19 |
Issue: |
5 |
Pages: |
626-630 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hutchenreuther J |
Year: |
2018 |
Journal: |
Matrix Biol |
Title: |
Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma. |
Volume: |
74 |
|
Pages: |
52-61 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang Q |
Year: |
2018 |
Journal: |
Cancer Res |
Title: |
TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis. |
Volume: |
78 |
Issue: |
14 |
Pages: |
3982-3994 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hutchenreuther J |
Year: |
2015 |
Journal: |
J Invest Dermatol |
Title: |
CCN2 Expression by Tumor Stroma Is Required for Melanoma Metastasis. |
Volume: |
135 |
Issue: |
11 |
Pages: |
2805-2813 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hao W |
Year: |
2023 |
Journal: |
Cell Death Dis |
Title: |
Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease. |
Volume: |
14 |
Issue: |
10 |
Pages: |
680 |
|
•
•
•
•
•
|
Publication |
First Author: |
Albinet V |
Year: |
2014 |
Journal: |
Oncogene |
Title: |
Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells. |
Volume: |
33 |
Issue: |
26 |
Pages: |
3364-73 |
|
•
•
•
•
•
|
Publication |
First Author: |
Shah R |
Year: |
2019 |
Journal: |
Cancer Res |
Title: |
Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma. |
Volume: |
79 |
Issue: |
8 |
Pages: |
1799-1809 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ingersoll MA |
Year: |
2024 |
Journal: |
J Neurosci |
Title: |
KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss. |
Volume: |
44 |
Issue: |
18 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Marais R |
Year: |
2013 |
Journal: |
Cancer Res |
Title: |
Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. |
Volume: |
73 |
Issue: |
3 |
Pages: |
1046-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Strickland LR |
Year: |
2015 |
Journal: |
Cancer Lett |
Title: |
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. |
Volume: |
359 |
Issue: |
1 |
Pages: |
20-35 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wargo JA |
Year: |
2014 |
Journal: |
Cancer Discov |
Title: |
Universes collide: combining immunotherapy with targeted therapy for cancer. |
Volume: |
4 |
Issue: |
12 |
Pages: |
1377-86 |
|
•
•
•
•
•
|
Publication |
First Author: |
Feng Y |
Year: |
2015 |
Journal: |
Cancer Res |
Title: |
SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. |
Volume: |
75 |
Issue: |
24 |
Pages: |
5211-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Mehrotra A |
Year: |
2014 |
Journal: |
Arch Biochem Biophys |
Title: |
Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation. |
Volume: |
563 |
|
Pages: |
125-35 |
|
•
•
•
•
•
|
Publication |
First Author: |
Laudisi F |
Year: |
2019 |
Journal: |
Cancer Lett |
Title: |
Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. |
Volume: |
462 |
|
Pages: |
1-11 |
|
•
•
•
•
•
|
Publication |
First Author: |
Laurette P |
Year: |
2020 |
Journal: |
Cell Death Differ |
Title: |
Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma. |
Volume: |
27 |
Issue: |
1 |
Pages: |
29-43 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bowman RL |
Year: |
2021 |
Journal: |
Life Sci Alliance |
Title: |
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma. |
Volume: |
4 |
Issue: |
9 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Kanazawa K |
Year: |
2021 |
Journal: |
Cancer Sci |
Title: |
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis. |
Volume: |
112 |
Issue: |
6 |
Pages: |
2233-2244 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kochi M |
Year: |
2020 |
Journal: |
Cancer Sci |
Title: |
Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer. |
Volume: |
111 |
Issue: |
10 |
Pages: |
3540-3549 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sánchez-Tilló E |
Year: |
2023 |
Journal: |
JCI Insight |
Title: |
The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas. |
Volume: |
8 |
Issue: |
20 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Bosso G |
Year: |
2024 |
Journal: |
Cell Death Differ |
Title: |
Differential contribution for ERK1 and ERK2 kinases in BRAF(V600E)-triggered phenotypes in adult mouse models. |
Volume: |
31 |
Issue: |
6 |
Pages: |
804-819 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kaul A |
Year: |
2015 |
Journal: |
Neuro Oncol |
Title: |
The impact of coexisting genetic mutations on murine optic glioma biology. |
Volume: |
17 |
Issue: |
5 |
Pages: |
670-7 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ryder M |
Year: |
2013 |
Journal: |
PLoS One |
Title: |
Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. |
Volume: |
8 |
Issue: |
1 |
Pages: |
e54302 |
|
•
•
•
•
•
|
Publication |
First Author: |
Su Q |
Year: |
2008 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
A DNA transposon-based approach to validate oncogenic mutations in the mouse. |
Volume: |
105 |
Issue: |
50 |
Pages: |
19904-9 |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Hprt1/Hprt1<+> |
Background: |
involves: 129S7/SvEvBrd |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Hprt1/? |
Background: |
involves: 129S7/SvEvBrd |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Genotype |
Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Ifi208/Ifi208<+> |
Background: |
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL |
Zygosity: |
cn |
Has Mutant Allele: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhou X |
Year: |
2019 |
Journal: |
Exp Neurobiol |
Title: |
Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease. |
Volume: |
28 |
Issue: |
3 |
Pages: |
390-403 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bongers G |
Year: |
2012 |
Journal: |
Gastroenterology |
Title: |
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. |
Volume: |
143 |
Issue: |
3 |
Pages: |
730-740 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tonks ID |
Year: |
2017 |
Journal: |
Oncogene |
Title: |
Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation. |
Volume: |
36 |
Issue: |
26 |
Pages: |
3789-3795 |
|
•
•
•
•
•
|
Publication |
First Author: |
Jacenik D |
Year: |
2023 |
Journal: |
Front Immunol |
Title: |
MK2 drives progression of pancreas and colon cancers by suppressing CD8(+) T cell cytotoxic function and is a potential immunotherapy target. |
Volume: |
14 |
|
Pages: |
1212100 |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
432
|
Fragment?: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Hitz C |
Year: |
2007 |
Journal: |
Nucleic Acids Res |
Title: |
Conditional brain-specific knockdown of MAPK using Cre/loxP regulated RNA interference. |
Volume: |
35 |
Issue: |
12 |
Pages: |
e90 |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
394
|
Fragment?: |
false |
|
•
•
•
•
•
|
Publication |
First Author: |
Mouse Genome Informatics Scientific Curators |
Year: |
2005 |
|
Title: |
Mouse Synonym Curation |
|
|
|
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
818
|
Fragment?: |
false |
|
•
•
•
•
•
|